ATX-101, an experimental form of sodium deoxycholate, reduced patients' submental fat in late-stage studies, co-developers Bayer Healthcare and Kythera Biopharmaceuticals report.
Published in Brief:
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan